​​​– Long-time advocate, Paris Hilton, shares her personal ADHD journey from childhood to adulthood to encourage others to speak to their healthcare provider about appropriate treatment options – STOUGHTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company, and Paris Hilton, entrepreneur, musician, ​author, and advocate, ​are collaborating ​​to share her personal experience living with attention-deficit/hyperactivity dis ...

Core Insights - Collegium Pharmaceutical, Inc. is presenting real-world data on its ADHD treatment product, Jornay PM, at the AACAP and NEI conferences, emphasizing its commitment to the ADHD community [1][2] Group 1: Product Information - Jornay PM is a CNS stimulant used for treating ADHD in individuals aged 6 and older, aimed at increasing attention and reducing impulsiveness and hyperactivity [11] - The product is scheduled for poster presentations at two major conferences: AACAP in Chicago from October 20-25, 2025, and NEI in Colorado Springs from November 6-9, 2025 [3][4] Group 2: Conference Details - The poster titled "Determining the Optimal Dose of Methylphenidate HCl (JORNAY PM) in Adolescents and Adults in a Real-World Psychiatric Setting" will be presented on October 22, 2025, from 4-6 p.m. CDT at the Hyatt Regency [3] - Another poster titled "JORNAY PM® in Practice: Real-World Evidence Exploration of Utilization and Patient Response" will be presented on November 7, 2025, from 4-5 p.m. MST at Broadmoor West, The Broadmoor [4] Group 3: Company Strategy - Collegium is focused on building a diversified biopharmaceutical company with a strong portfolio in pain management and a growing neuropsychiatry business, with ADHD as a key growth driver [14]